JP2016518321A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518321A5
JP2016518321A5 JP2016501214A JP2016501214A JP2016518321A5 JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5 JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5
Authority
JP
Japan
Prior art keywords
range
rfviii
formulation
ppm
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023357 external-priority patent/WO2014150477A1/en
Publication of JP2016518321A publication Critical patent/JP2016518321A/ja
Publication of JP2016518321A5 publication Critical patent/JP2016518321A5/ja
Pending legal-status Critical Current

Links

JP2016501214A 2013-03-15 2014-03-11 組み換え因子ｖｉｉｉ配合物 Pending JP2016518321A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US61/799,495 2013-03-15
US201361869191P 2013-08-23 2013-08-23
US61/869,191 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (2)

Publication Number Publication Date
JP2016518321A JP2016518321A (ja) 2016-06-23
JP2016518321A5 true JP2016518321A5 (https=) 2017-04-13

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501214A Pending JP2016518321A (ja) 2013-03-15 2014-03-11 組み換え因子ｖｉｉｉ配合物

Country Status (17)

Country Link
US (1) US20160030524A1 (https=)
EP (1) EP2970430A4 (https=)
JP (1) JP2016518321A (https=)
KR (1) KR20150132449A (https=)
CN (1) CN105209487A (https=)
AU (1) AU2014237111B2 (https=)
BR (1) BR112015022730A2 (https=)
CA (1) CA2905739A1 (https=)
HK (1) HK1213273A1 (https=)
MX (1) MX2015012905A (https=)
PE (1) PE20160121A1 (https=)
RU (1) RU2015144076A (https=)
SG (2) SG11201507618YA (https=)
TW (1) TW201521761A (https=)
UY (1) UY35412A (https=)
WO (1) WO2014150477A1 (https=)
ZA (1) ZA201507684B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EP3374387A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
EP2921180B1 (en) * 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
NZ593190A (en) * 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety

Similar Documents

Publication Publication Date Title
JP2016518321A5 (https=)
JP2016515515A5 (https=)
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
UA125223C2 (uk) СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
MX2020009000A (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido.
GEAP202114794A (en) Antibody neutralizing human respiratory syncytial virus
JP2022533318A (ja) 気道感染の治療または予防のためのサブユニットワクチン
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
MX2021004015A (es) Compuestos de aminoacidos y metodos de uso.
Carignan et al. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine
JP2009017881A5 (https=)
JP2019504086A5 (https=)
JP2010511665A5 (https=)
ES2791954T3 (es) Nuevo antagonista de TLR4
AU2015252569A1 (en) Methods and compositions for modulating the immune system with Arginase l
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
JP2015500827A5 (https=)
NZ700686A (en) Uses of casein compositions
JP2016520075A5 (https=)
JP2012136518A5 (https=)
RU2015144076A (ru) Композиции рекомбинантного фактора viii
WO2018134389A1 (en) Methods and compositions for treating infections
JP2015519359A5 (https=)